George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccsys Tech Regulatory News (AXS)

Share Price Information for Accsys Tech (AXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.00
Bid: 56.00
Ask: 56.40
Change: -0.30 (-0.53%)
Spread: 0.40 (0.714%)
Open: 56.00
High: 56.00
Low: 56.00
Prev. Close: 56.50
AXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim results

22 Nov 2016 07:00

RNS Number : 7635P
Accsys Technologies PLC
22 November 2016
 

 

AIM: AXS

Euronext Amsterdam: AXS

 

22 November 2016

 

ACCSYS TECHNOLOGIES PLC ("Accsys" or "the Company")

 

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

 

Accsys, the chemical technology group, focused on the acetylation of wood, today announces interim results for the consolidated group for the six months ended 30 September 2016.

 

 

Unaudited six

Unaudited six

 

months ended

months ended

 

30 Sept 2016

30 Sept 2015

Accoya® revenue

€22.5m

€21.9m

Total Revenue

€25.1m

€26.3m

Gross Profit

€6.8m

€9.4m

EBITDA

€(1.3m)

€1.3m

Loss before taxation

€(2.9m)

€(0.1m)

Period end cash balance

€7.9m

€7.5m

 

 

See note 2 of the Group financial statements for reconciliation of Operating loss to EBITDA

 

Financial highlights

· Demand for Accoya continues to grow with sales volumes increasing by 4% to 17,506m3 and with growth accelerating into the second half of the financial year;

· Group revenue decreased by 5% due to an expected reduction in licence related income and an unexpected supply chain bottleneck which has now been resolved;

· Further licensing income expected in the second half of the financial year;

· A number of factors contributed to a lower EBITDA including lower licence related income, timing of annual plant maintenance stop, a new pricing regime with Solvay and higher costs associated with the proposed Tricoya consortium; and

· A cash balance of €7.9m at 30 September 2016 (31 March 2016: €8.2m) reflects operating loss in the period and new plant investment, off-set by €4.2m proceeds from the sale of land in Arnhem.

Operational highlights

· Building work commenced on the expansion of Accoya manufacturing plant in Arnhem;

· We remain on track to increase manufacturing capacity by 20,000m3 by December 2017;

· Significant progress has been made towards completion of the proposed Tricoya consortium with BP and Medite with final agreements, including funding from third parties, expected later this year; and

· Detailed planning progressing in respect of the wood chip acetylation plant to be located in Hull.

 

Paul Clegg, Chief Executive commented: "In this financial period we have made further significant strategic and operational progress to increase our Accoya and Tricoya manufacturing capacity which will be transformational for the Group. The expansion of the Accoya plant in Arnhem and the formation of the Tricoya consortium are both fundamental for the future of the Company. Despite results being down on the previous half year, we remain confident of the results for the full year and beyond."

 

There will be a presentation relating to these results at 10:00 GMT on 22 November 2016. The presentation will take the form of a web based conference call, details of which are below:

 

Webcast link:

 

Click here or copy and paste ALL of the following text into your browser:

 

http://edge.media-server.com/m/p/bcsg2woj

 

Conference call details for participants:

 

Confirmation Code: 

2293862

Participants, Local - London, United Kingdom:

+44(0)20 3450 9987

Participants, National free phone - United Kingdom:

0800 279 4992

    

 

Participants will have to quote the above code when dialling into the conference.

 

For further information, please contact:

 

Accsys Technologies PLC

Paul Clegg, CEO

Hans Pauli, Executive Director, Corporate Development

Will Rudge, FD

 

 via MHP Communications

Numis Securities

Nominated Adviser: Oliver Cardigan

Jamie Lillywhite

Corporate Broking: Christopher Wilkinson

Ben Stoop

+44 (0) 20 7260 1000

 

MHP Communications

Tim Rowntree

Kelsey Traynor

 

+44 (0) 20 3128 8100

Off the Grid (The Netherlands)

 

Frank Neervoort

Yvonne Derkse

 

+31 681 734 236

+31 622 379 666

 

Accsys Technologies PLC

 

Chairman's statement

 

Overview

We have made good progress in the period, in particular with two major projects intended to significantly increase manufacturing capacity for Accoya and Tricoya. These will ultimately enable us to substantially increase our revenue, through additional capacity and generate profitability whilst enabling us to exploit our products and technologies in what we continue to believe is a very significant market.

 

Sales of Accoya continued to grow with total sales volumes increasing by 4% to 17,506m3. We experienced supply bottleneck issues in the period which, although these have now been resolved, will necessitate further investment in inventory going forward. Further sales growth is expected in the second half of the year. This will continue to be constrained until the expansion of our manufacturing facility in Arnhem is completed. Total revenue decreased by 5% to €25.1m (2015: €26.3m) largely as result of an expected reduction in lower income associated with our licensing contract with Solvay.

 

Group EBITDA was a loss of €1.3m for the period with the reduction from last year primarily resulting from the lower licence related income noting that the prior year included €1.8m of one-off licensing related income. In addition, profitability was impacted by the timing of our annual maintenance stop moving back to September compared to October last year, together with a proportion of Accoya sales sold at lower prices to Solvay from January 2016 following their assumption of responsibility for sales and marketing and the commencement of the 76,000m3 five year off-take agreement. Operating costs increased by 9% in the period to €10.2m largely as a result of business development activities as we actively pursued long term opportunities and incurred one-off advisory fees.

 

Our cash balance decreased to €7.9m at 30 September 2016 from €8.2m at 31 March 2016. A €2.7m cash out-flow was partly attributable to the loss in the period, and also impacted by a €1.1m working capital out-flow. €1.8m was invested during the period in our existing manufacturing operations together with the initial stages and planning work associated with the Arnhem expansion and the proposed Tricoya plant. This was off-set by €4.2m proceeds from the sale of our land adjacent to our plant in Arnhem, which also resulted in a gain on disposal of €0.6m.

 

We have commenced construction work in respect of the expansion of our Accoya manufacturing plant in Arnhem. We have obtained all necessary permits, completed the sale and leaseback of our land and placed orders for key long lead time items of equipment. Work has commenced on site and we appointed Fabricom B.V. as the Engineering, Procurement and Construction contractor enabling the third reactor to be built by the end of 2017, increasing our manufacturing capacity by 50% to approximately 60,000m3.

 

We have also made significant progress towards the completion of the proposed Tricoya consortium with BP and Medite, to build and operate the world's first wood chip acetylation plant on the Saltend Chemicals Park in Hull. The parties expect to finalise the detailed agreements associated with the site and the consortium by the end of this year. In addition, substantial progress has been made in respect of the remaining funding, with term sheets obtained in respect of bank debt and non-binding heads of terms agreed with third party funders which are expected to enable the consortium to proceed. Under these arrangements Accsys is expected to retain the majority ownership of the consortium and consolidate its results.

 

 

Outlook 

I am pleased by the progress made towards achieving additional manufacturing capacity for both Accoya and Tricoya. I believe these represent key milestones in our ambition to maximise the value associated with our technologies, and will enable us to meet the demand for our products, with significant benefits to our profitability.

Demand for Accoya and Tricoya remains strong and we were disappointed that we could not satisfy demand in the first half due to the supply bottleneck issues. These are now resolved and we expect sales volumes to continue to grow in the immediate term, although such growth will be limited until our new manufacturing capacity comes on stream.

Overall, I continue to be confident that we are in a strong position and look forward to reporting further progress in respect of the Tricoya consortium in the near future.

 

 

Patrick Shanley

Chairman

21 November 2016

 

 

Accsys Technologies PLC

 

Chief Executive's statement

 

Introduction

 

Accsys has taken important steps towards securing additional manufacturing capacity and in turn being able to meet the substantial opportunity which exists to monetise our products and technology.

 

We have been very busy progressing the two major projects for the Group; the expansion of our Accoya manufacturing plant and the completion of the proposed Tricoya consortium to build the new Tricoya Plant in Hull. Demand remains strong for Accoya and we have been focused on ensuring the additional manufacturing capacity is built by the end of the next calendar year to meet this demand and grow sales.

 

Progress with Accoya® manufacturing and sales

 

Revenue from the sale of Accoya® increased by 3% to €22.5m in the first half of the year compared to a particularly strong period in the previous year. The increase was attributable to a 4% increase in Accoya volumes sold to 17,506m3. The relatively small increase reflects supply chain bottleneck issues that resulted in us being unable to meet some sales potential. These issues are now resolved but in the future we will need to invest in further inventory as sales grow. We will continue to manage demand as we approach the maximum capacity of our existing manufacturing plant.

 

Demand for Accoya continues to remain strong, and we continue to believe the overall market opportunity is in excess of 1 million m3 annually. It remains very strong in the UK with no impact from the Brexit result having so far been evident. We have previously reported that the Benelux economies experienced a prolonged period of downturn in the construction industry and some of our customers were particularly impacted. We are now seeing an improvement and increased level of activity with sales increasing in Belgium, but with sales and marketing in the Netherlands requiring additional focus that is now under way.

 

Sales in Solvay's region, covering key states in central Europe and Scandinavia, decreased following the immediate transition of responsibility to Solvay on 1 January 2016, however we are pleased that the transition has otherwise gone smoothly and we expect sales to increase in the immediate future. Sales to North America have increased strongly following the addition of new sales team members last year and we continue to believe the region represents a substantial opportunity in the longer term.

 

We have 61 Accoya distributor, supply and agency agreements in place covering most of Europe, Australia, Canada, Chile, China, India, Israel, Mexico, Morocco, New Zealand, South Africa, parts of South-East Asia and Middle-East and the USA.

 

The gross manufacturing margin of 25%, which compared to 30% in the same period last year, was impacted by the timing of our annual maintenance stop and pricing. No price increases were implemented in the period, however sales to Solvay from 1 January 2016 were at a lower price to reflect Solvay taking responsibility for sales and commitment to buy a minimum of 76,000m3 over a five-year period.

 

Our annual maintenance period, during which no Accoya is produced, took place in September 2016 compared to October 2015, resulting in increased costs in this period. The underlying manufacturing margin however continues to benefit from economies of scale associated with higher manufacturing volumes and this is expected to improve in the second half of the year. The 25% margin represents an increase compared to the 23% recorded in the second half of the last financial year.

 

The manufacturing segment's profitability helps demonstrate the potential returns achievable from manufacturing Accoya® on an even larger scale. This will be particularly relevant when we benefit from the economies of scale expected from operating a larger plant. Also our profitability has been impacted by significant volumes (approximately 16% of total Accoya® volume in the period (2015: 18%)) sold to Medite at lower prices, reflecting the on-going Tricoya market development activities as well as the reduced prices for Accoya sold to Solvay under the five year off-take agreement.

 

 

Expansion of Accoya capacity in Arnhem

 

We have made good progress in respect of the expansion of our Accoya manufacturing plant in Arnhem. During the period we have obtained all necessary permits, which has enabled us to start work on site.

 

We completed the sale of the land adjacent to our existing plant to the same purchaser who acquired the existing plant's land and buildings in 2011 and 2012. The sale resulted in proceeds of €4.2m and a gain on sale of the land of €0.6m. The landlord has commenced work on building a warehouse and new office building which will connect to our existing plant and enable us to operate the expanded plant more efficiently.

 

We have placed the order for the third reactor, a key item of equipment with a long lead-time. In addition, we have recently appointed Fabricom B.V. as the EPC (Engineering, Procurement and Construction) contractor who will carry out the majority of the work on site. The expansion is expected to be complete by the end of 2017 with sales growth expected to increase thereafter. This is expected to initially include increased sales to Medite to enable further market development ahead of the dedicated wood chip acetylation plant in Hull becoming operational.

 

The expansion involves the addition of a third reactor which will increase the capacity of the plant to approximately 60,000m3, enabling Accoya manufacturing revenue to increase to in excess of €80m over time. In addition, this first stage of the expansion includes the full chemical infrastructure in readiness for a fourth reactor to be added at a later date when needed, increasing capacity by a further 20,000m3. The capital expenditure for this first stage of the expansion is being funded by a loan from Solvay, incremental fees due from Solvay, including fees expected in the second half of the financial year, together with the Group's internal financial resources.

 

The expansion allows the market development of Accoya to continue at the fastest pace possible, increasing the certainty of supply for Accoya customers and users. It also enables Accsys to continue to develop global markets effectively, building on the expertise that it has developed over the last few years.

 

The significant market opportunity also requires us to invest in developing our supply chain to ensure that Accsys is able to secure our necessary raw materials to meet the demand over the longer term.

 

Tricoya Technologies Limited ('TTL')

 

In February 2016 we announced BP's participation in the proposed consortium (the 'Consortium') to fund, build and operate the world's first Tricoya® wood elements acetylation plant. Accsys and BP Ventures ('BPV') agreed initial funding in respect of the Consortium, with BPV acquiring an initial 3% equity interest in Tricoya Technologies Limited , implying a valuation of TTL at €35 million.

 

Since then, significant progress has been made with our Consortium partners, BP and Medite, in respect of detailed planning and the agreements associated with the Consortium and the proposed wood chip acetylation plant. The Hull plant will have an initial capacity of 30,000 tonnes per annum (tpa) (sufficient to manufacture 40,000m³ of panels) with scope for expansion. A minimum of 40% of the plant's output is expected to be sold to Medite under committed take-or-pay agreements, which corresponds to break-even cash flow level. The plant is expected to cost approximately €62m, with a further €14m required for continued market seeding, operations, marketing, IP development and engineering functions.

 

Final agreements relating to the Consortium, the site, the supply of chemicals from BP and the off-take agreement with Medite are expected to be completed by the end of the year. BP and Medite are also expected to invest a total of €30m with the remainder funded by third parties, including bank debt. In this respect, the Consortium has also made good progress on securing finance with term sheets received from a number of providers of project finance debt and heads of terms agreed with further third party providers of finance which is expected to result in sufficient funding to allow the Consortium to be completed. The agreements are expected to result in Accsys consolidating the Consortium, retaining a majority ownership of the shares.

 

Subsequent to the period end, the Consortium parties agreed further interim funding to enable the next stages of the project to progress, including the land clearance of the site in Hull and initial steps associated with the detailed engineering.

 

 

 

Medite Tricoya® has continued to be manufactured during the period using Accoya sold by Accsys to Medite using a temporary process, pending construction of the dedicated Tricoya plant. This has enabled sales of Medite Tricoya to grow, with sales volumes of Medite Tricoya panels increasing by 39% in the calendar year to September. The increasing sales continue to support our belief that in time, sales of Tricoya panels could exceed 1.6 million m3 per annum.

 

Intellectual property

 

Accsys has increased its number of patent applications in the recent period by expanding its patent families to 23, including those relating to Tricoya®. Applications filed now number 198, filed in 43 countries. To date 45 patents have been granted in various countries throughout the world.

 

Our principal trademark portfolio remains unchanged with our brands Accoya®, Tricoya®, the Trimarque device and Accsys®, including transliterations in Arabic, Chinese and Japanese, protected by registration in 56 countries.

 

The Company continues to invest in the generation and protection of valuable know-how and confidential information relating to its products and processes.

 

Outlook

 

The start of our Accoya plant expansion is a key milestone for the Company. The initial 50% increase in capacity will help us to meet customer demand and will also increase our profitability as we benefit from economies of scale and strive to improve our manufacturing efficiency. This will strengthen Accsys financially and will better position us to take advantage of the significant opportunity that we continue to believe exists to monetise our intellectual property.

 

The proposed Tricoya Consortium is an exciting prospect and the parties are working hard to conclude the necessary agreements and funding later this year, which will enable the first plant to be built. This would represent a further significant increase in our overall manufacturing capability and another route to monetise our intellectual property.

 

In the shorter term we will continue to grow the Accoya market in key regions by focusing on sales and marketing activities, which enable us to develop underlying demand and market acceptance while at the same time managing the demand ahead of new capacity becoming on stream by the end of next year.

 

 

Paul Clegg

Chief Executive

21 November 2016

 

Accsys Technologies PLC

 

Financial Review

 

Statement of comprehensive income

 

Group revenue decreased by 5% to €25.1m for the six months ended 30 September 2016 (2015: €26.3m). Manufacturing revenue increased by 1% to €24.4m, with revenue from Accoya® increasing by 3% to €22.5m, largely as a result of higher sales volumes. Included in this is revenue attributable to Medite for the manufacture of Tricoya®, which decreased by 2% to €2.7m (2015: €2.8m) largely due to timing of deliveries, noting that Medite's own sales continued to grow in excess of 30%. Licensing and business development revenue of €0.7m (2015: €2.2m) was attributable to our Accoya licensee, Solvay, in respect of the commencement of the Arnhem expansion and marketing services. The prior year included €1.3m in respect of the expired Global Marketing agreement with Solvay with a further €0.5m of income recorded in respect of monies received attributable to the Tricoya project, neither of which was repeated in the current period.

 

Gross margin decreased from 36% to 27% compared to the same period in the previous year largely due to the reduction in licence related income as described above and an increase in cost of sales. Gross manufacturing margin decreased from 30% to 25% due to the impact of the timing of the annual maintenance stop, noting that the gross manufacturing margin in the second half of the last financial year, which included the annual maintenance stop, was 23%. In addition there was a reduction in pricing to Solvay effective from 1 January 2016 on the assumption by Solvay of responsibility for sales and marketing associated with their 76,000m3 five-year off-take agreement.

 

Other operating costs, increased from €9.4m to €10.2m. Staff costs increased by €0.2m to €4.8m due to annual inflation salary increases, an increase in headcount and a change to management bonuses in which a larger proportion was paid in cash rather than deferred shares compared to previous periods. This increase was mitigated as our UK cost base benefited from the strengthening of the Euro against Sterling during the period. The Group has undertaken various business development projects including incurring costs associated with the Arnhem expansion, the proposed Tricoya consortium and pursuing other long term opportunities which also contributed to the increase by €0.4m. The remaining increase in costs was largely attributable to corporate head office costs.  

 

Research and development costs decreased from €0.8m to €0.6m as a result of an increase in internal activities which have been capitalised as intangible assets. See note 7.

 

Full details of TTL's results have been included in note 6.

 

Group average headcount increased from 119 in the period to 30 September 2015, to 120 in the period to 31 March 2016 and 124 in the period to 30 September 2016, with the increase predominantly attributable to temporary staff supporting the two major projects.

 

The increase in the loss before tax by €2.8m to €2.9m (2015: €0.1m) can largely be attributed to the lower revenue and gross margin.

 

The tax charge of €0.4m (2015: €0.2m) is based on our expected tax rate for the year and is attributable to the profits arising from manufacturing operations, offset by expected research and development tax credits.

 

 

 

Cash flow and financial position

 

At 30 September 2016, the Group held cash balances of €7.9m, representing a €0.3m reduction compared to 31 March 2016. The reduction in cash in the period is attributable to an increase in working capital of €1.1m, investment in tangible and intangible fixed assets of €1.8m, out-flows from operating activities of €1.5m and offset by the proceeds from the sale of land of €4.2m.

 

Cash out-flow from operating activities before changes in working capital of €1.5m represented a decrease compared to €1.8m cash in-flow in the equivalent period in the previous year, reflecting the underlying decline in profits of the Group. The change in working capital in the six months to September 2016 of €1.1m (2015: €3.3m) included an increase relating to inventories of €1.7m in the period due to the expected increase in sales in the second half of the year and our need to build inventory levels generally to satisfy customer demand. There was also an increase in trade and other receivables of €0.8m and trade and other payables of €1.4m due to shorter-term working capital fluctuations.

 

Investment in tangible fixed assets of €1.5m (2015: €0.7m) consisted predominantly of equipment and services in respect of the Accoya plant expansion and equipment subsequently installed during the maintenance stop in September which is expected to result in improved efficiency and reliability of the plant. €0.2m of capitalised internal development costs consisted predominantly of capitalised costs in respect of Tricoya Technologies Limited (2015: €1.2m, included capitalised costs associated with the pre-construction engineering for the Hull plant).

 

Trade and other receivables increased to €6.4m (2015: €4.3m) largely as a result of an increase in pre-paid inventory due to be received shortly after the period end in order to satisfy the expected higher sales in the second half of the year compared to the second half of the prior year. Inventory otherwise decreased marginally to €10.2m compared to September 2015 (2015: €10.3m). 

 

The increase in trade and other payables to €9.5m (2015: €8.1m) includes the expenses associated with various projects currently being undertaken by the Group such as the Arnhem plant expansion, Tricoya Technologies Limited plant construction and business development activities.

 

Risks and uncertainties

 

The Group's principal risks and uncertainties are unchanged from those set out in its 2016 Annual Report. In addition, as described above, there is a risk associated with ensuring that our supply chain is able to meet the demand associated with the increasing sales. The Group expects to further invest in inventory going forward as part of the strategy to ensure there are no supply chain bottlenecks.

 

Going concern

 

These condensed consolidated financial statements are prepared on a going concern basis, which assumes that the Group will continue in operational existence for the foreseeable future, which is deemed to be at least 12 months from the date these interim results were approved. As part of the Group's going concern review, the Directors have reviewed the Group's trading forecasts and working capital requirements for the foreseeable future. These forecasts indicate that, in order to continue as a going concern, the Group is dependent on achieving certain operating performance measures relating to the production and sales of Accoya® wood from the plant in Arnhem and the collection of on-going working capital items in line with internally agreed budgets.

 

The Directors have considered the internally agreed budgets and performance measures and believe that appropriate controls and procedures are in place or will be in place to make sure that these are met. The Directors believe, while some uncertainty inherently remains in achieving the budget, in particular in relation to market conditions outside of the Group's control, that there are a sufficient number of alternative actions and measures that can be taken in order to achieve the Group's medium and long term objectives.

 

Therefore, the Directors believe that the going concern basis is the most appropriate basis on which to prepare the financial statements.

 

William Rudge

Finance Director

21 November 2016

 

 

Accsys Technologies PLC

 

Directors responsibility statement

 

The Directors confirm to the best of their knowledge:

 

· The Group financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRSs') as adopted by the European Union and Article 4 of the IAS Regulation and give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group.

 

· The interim results include a fair review of the information required by DTR 4.2.7R being an indication of important events that have occurred during the first six months of the financial year and a description of the principal risks and uncertainties for the remaining six months of the financial year; and

 

· The interim Management Report (Narrative) include a fair review of the information required by DTR 4.28R being disclosure of related party transactions and changes therein since the last annual report.

 

 

By order of the Board

 

 

 

Angus Dodwell

Company Secretary

21 November 2016

   

 

Accsys Technologies PLC

 

Consolidated interim statement of comprehensive income for the six months ended 30 September 2016

 

 

Note

 

Unaudited

Unaudited

Audited

 

 

 

6 months

6 months

Year

 

 

 

ended

ended

ended

 

 

 

30 Sept

30 Sept

31 March

 

 

 

2016

2015

2016

 

 

 

€'000

€'000

€'000

 

 

 

Total

Total

Total

 

 

 

 

 

 

Accoya® wood revenue

 

 

22,534

21,862

43,466

Licence revenue

 

 

500

328

2,849

Other revenue

 

 

2,025

4,104

6,454

 

 

 

 

 

 

Total revenue

2

 

25,059

26,294

52,769

 

 

 

 

 

 

Total cost of sales

 

 

(18,236)

(16,916)

(34,597)

 

 

 

 

 

 

Gross profit

 

 

6,823

9,378

18,172

 

 

 

 

 

 

Other operating costs

3

 

(10,176)

(9,389)

(18,460)

Other gains

4

 

601

-

-

 

 

 

 

 

 

Loss from operations

 

 

(2,752)

(11)

(288)

 

 

 

 

 

 

Finance income

 

 

1

16

13

Finance expense

 

 

(104)

(98)

(191)

 

 

 

 

 

 

Loss before taxation

 

 

(2,855)

(92)

(466)

 

 

 

 

 

 

Tax charge

 

 

(373)

(240)

(402)

 

 

 

 

 

 

Loss for the period

 

 

(3,228)

(332)

(868)

 

 

 

 

 

 

Gain arising on translation of foreign operations

 

 

-

33

(27)

 

 

 

 

 

 

Total comprehensive loss for the period

 

 

(3,228)

(299)

(895)

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss for the year is attributable to:

 

 

 

 

 

Owners of Accsys Technologies PLC

 

 

(3,186)

(299)

(885)

Non-controlling interests

 

 

(42)

-

(10)

 

 

 

 

 

 

Total comprehensive loss for the period

 

 

(3,228)

(299)

(895)

 

 

 

 

 

 

Basic and diluted loss per ordinary share

5

 

€(0.04)

€(0.00)

€(0.01)

 

 

 

 

 

 

 

The notes set out on pages 15 to 24 form an integral part of these condensed financial statements.

 

 

 

 

 

Accsys Technologies PLC

 

Consolidated interim statement of financial position at 30 September 2016

 

 

 

Unaudited

Unaudited

Audited

 

 

6 months

6 months

Year

 

 

ended

ended

ended

 

 

30 Sept

30 Sept

31 March

 

Note

2016

2015

2016

 

 

€'000

€'000

€'000

 

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

7

10,945

10,965

10,980

Property, plant and equipment

8

16,914

19,201

20,272

 

 

 

 

 

 

 

 

 

 

 

 

27,859

30,166

31,252

Current assets

 

 

 

 

Inventories

 

10,184

10,272

8,345

Trade and other receivables

 

6,441

4,267

5,647

Cash and cash equivalents

 

7,866

7,501

8,186

Corporation tax

 

545

470

412

 

 

 

 

 

 

 

25,036

22,510

22,590

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

(9,455)

(8,136)

(8,063)

Obligation under finance lease

 

(347)

(265)

(354)

Corporation tax

 

(1,929)

(1,132)

(1,425)

 

 

 

 

 

 

 

(11,731)

(9,532)

(9,842)

 

 

 

 

 

Non-current liabilities

 

 

 

 

Obligation under finance lease

 

(1,868)

(1,759)

(1,947)

 

 

 

 

 

 

 

(1,868)

(1,759)

(1,947)

 

 

 

 

 

Net current assets

 

13,305

12,978

12,748

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total net assets

 

39,296

41,385

42,053

 

 

 

 

 

 

 

 

 

 

Equity and reserves

 

 

 

 

Share capital - Ordinary shares

9

4,531

4,489

4,495

Share premium account

 

128,792

128,779

128,792

Other reserves

10

107,421

106,855

107,441

Retained deficit

 

(201,586)

(198,839)

(198,842)

Own shares

 

(34)

(46)

(47)

Foreign currency translation reserve

 

153

147

153

 

 

 

 

 

Capital value attributable to Accsys Technologies PLC

 

39,277

41,385

41,992

 

 

 

 

 

Non-controlling interest in subsidiary

 

19

-

61

 

 

 

 

 

 

 

 

 

 

Total equity

 

39,296

41,385

42,053

 

 

 

 

 

 

 

 

 

 

The notes set out on pages 15 to 24 form an integral part of these condensed financial statements.

 

 

Accsys Technologies PLC

 

Consolidated interim statement of changes in equity for the 6 months ended 30 September 2016

 

Share capital Ordinary

Share premium

Other reserves

Own Shares

Foreign currency trans-lation reserve

Retained earnings

 Total equity attributable to equity shareholders of the company

 Non-Controlling interests

 Total Equity

 

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

Balance at30 Sept 2015(unaudited)

4,489

128,779

106,855

(46)

147

(198,839)

41,385

-

41,385

 

 

 

 

 

 

 

 

 

-

Total comprehensive income/(expense) for the period

-

-

-

-

6

(526)

(520)

(10)

(530)

Share based payments

-

-

-

-

-

523

523

-

523

Shares issued

6

-

-

(1)

-

-

5

-

5

Premium on shares issued

-

13

-

-

-

-

13

-

13

Issue of subsidiary shares to non-controlling interests

-

-

586

-

-

-

586

71

657

 

 

 

 

 

 

 

 

 

 

Balance at31 March 2016

4,495

128,792

107,441

(47)

153

(198,842)

41,992

61

42,053

 

 

 

 

 

 

 

 

 

 

Total comprehensive expense for the period

-

-

-

-

(0)

(3,186)

(3,186)

(42)

(3,228)

Share based payments

-

-

-

-

-

442

442

-

442

Shares issued

36

-

-

13

-

-

49

-

49

Issue of subsidiary shares to non-controlling interests

-

-

(20)

-

-

-

(20)

-

(20)

 

 

 

 

 

 

 

 

 

 

Balance at30 Sept 2016(unaudited)

4,531

128,792

107,421

(34)

153

(201,586)

39,277

19

39,296

 

 

 

 

 

 

 

 

 

 

 

 

See note 8 for details concerning other reserves.

 

Non-controlling interests relates to the investment of BP Ventures into Tricoya Technologies Limited (note 6)

 

The notes set out on pages 15 to 24 form an integral part of these condensed financial statements.

 

 

 

 

  

 

 

Accsys Technologies PLC

 

Consolidated interim statement of cash flow for the six months ended 30 September 2016

 

 

 

Unaudited

Unaudited

Audited

 

 

6 months

6 months

Year End

 

 

30 Sept

30 Sept

31 March

 

 

2016

2015

2016

 

 

€'000

€'000

€'000

 

 

 

 

 

Loss before taxation

 

(2,855)

(92)

(466)

Adjustments for:

 

 

 

 

Amortisation of intangible assets

 

276

254

524

Depreciation of property, plant and equipment

 

1,090

1,075

2,148

Net (gain)/loss on disposal of property, plant and equipment

 

(601)

(3)

35

Net Finance expense

 

103

82

177

Equity-settled share-based payment expenses

 

442

515

1,038

 

 

 

 

 

Cash outflows from operating activities before changes in working capital

 (1,545)

1,831

3,456

 

 

 

 

 

Decrease/(Increase) in trade and other receivables

 

(765)

609

(714)

(Decrease)/Increase in deferred income

 

(23)

(1,586)

(1,661)

(Decrease)/Increase in inventories

 

(1,712)

(2,379)

(453)

(Increase)/Decrease in trade and other payables

 

1,394

203

(176)

 

 

 

 

 

Net cash absorbed by operating activities before tax

 

(2,651)

(1,322)

452

 

 

 

 

 

Tax (paid)/received

 

(2)

(2)

229

 

 

 

 

 

Net cash absorbed by operating activities

 

(2,653)

(1,324)

681

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

Interest received

 

1

17

5

Expenditure on intangible assets

 

(244)

(1,206)

(1,490)

Disposal of property, plant and equipment

 

4,223

2

3

Purchase of property, plant and equipment

 

(1,507)

(728)

(2,565)

 

 

 

 

 

Net cash absorbed by investing activities

 

2,473

(1,915)

(4,047)

 

 

 

 

 

Cashflows from financing activities

 

 

 

 

Repayment of finance lease

 

(86)

(39)

(106)

Interest Paid

 

(104)

(98)

(191)

Proceeds from issue of share capital

 

50

107

1,124

Share issue costs

 

-

-

(44)

 

 

 

 

 

Net cash from financing activities

 

(140)

(30)

783

 

 

 

 

 

Net decrease in cash and cash equivalents

 

(320)

(3,269)

(2,583)

Effect of exchange loss on cash and cash equivalents

 

-

(16)

(15)

Opening cash and cash equivalents

 

8,186

10,786

10,786

 

 

 

 

 

Closing cash and cash equivalents

 

7,866

7,501

8,186

 

 

 

 

 

 

The notes set out on pages 15 to 24 form an integral part of these interim financial statements.

 

Accsys Technologies PLC

 

Notes to the financial statements for the 6 months ended 30 September 2016

 

1. Accounting policies

 

General Information

 

The principal activity of the Group is the production and sale of Accoya® solid wood and exploitation of technology for the production and sale of Accoya® wood and Tricoya® wood elements via the Company's 100% owned subsidiaries, Titan Wood Limited, Titan Wood B.V., Titan Wood Technology B.V., Titan Wood Inc. and 97% owned subsidiary, Tricoya Technologies Limited (collectively the 'Group'). Manufactured through the Group's proprietary acetylation processes, these products exhibit superior dimensional stability and durability compared with alternative natural, treated and modified woods as well as more resource intensive man-made materials.

 

The Company is a public limited company, which is listed on AIM in the United Kingdom and Euronext in the Netherlands, and is domiciled in the United Kingdom. The registered office is Brettenham House, 19 Lancaster Place, London, WC2E 7EN.

 

The condensed consolidated interim financial statements were approved on 21 November 2016.

 

These condensed consolidated interim financial statements have been reviewed, not audited.

 

Basis of accounting

 

The Group's condensed financial statements in these interim results have been prepared in accordance with IFRS issued by the International Accounting Standards Board as endorsed by the European Union, in particular International Accounting Standard (IAS) 34 "interim financial reporting". The financial information for the six months ended 30 September 2016 and the six months ended 30 September 2015 is unaudited. The comparative financial information for the full year ended 31 March 2016 does not constitute the group's statutory financial statements for that period although it has been derived from the statutory financial statements for the year then ended. A copy of those statutory financial statements has been delivered to the Registrar of Companies and which were approved by the Board of Directors on the 14 June 2016. The auditors' report on those accounts was unqualified and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.

 

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

 

In preparing these interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended 31 March 2016.

 

The accounting policies adopted are consistent with those of the previous financial year except for taxes on income in the interim periods which are accrued using the tax rate that would be applicable to the expected total annual profit or loss.

 

Changes in accounting policies

 

No new accounting standards, amendments or interpretations have been adopted in the period which have any impact on these condensed financial statements, or are expected to affect the Group's 2017 Annual Report other than as noted below. The accounting policies and methods of computation are consistent with those applied in the 31 March 2016 annual financial statements.

 

Going concern

 

These condensed consolidated financial statements are prepared on a going concern basis, which assumes that the Group will continue in operational existence for the foreseeable future, which is deemed to be at least 12 months from the date these interim results were approved. As part of the Group's going concern review, the Directors have reviewed the Group's trading forecasts and working capital requirements for the foreseeable future. These forecasts indicate that, in order to continue as a going concern, the Group is dependent on achieving certain operating performance measures relating to the production and sales of Accoya® wood from the plant in Arnhem and the collection of on-going working capital items in line with internally agreed budgets.

 

The Directors have considered the internally agreed budgets and performance measures and believe that appropriate controls and procedures are in place or will be in place to make sure that these are met. The Directors believe, while some uncertainty inherently remains in achieving the budget, in particular in relation to market conditions outside of the Group's control, that there are a sufficient number of alternative actions and measures that can be taken in order to achieve the Group's medium and long term objectives. Therefore, the Directors believe that the going concern basis is the most appropriate on which to prepare the financial statements.

 

 

2. Segmental reporting

 

The Group's business is the development, commercialisation and licensing of proprietary technology for the manufacture of Accoya® wood, Tricoya® wood elements and related acetylation technologies. Segmental reporting is divided between licensing activities, the manufacturing and sale of Accoya® and research and development activities.

Result by Segment:

Licensing, management and business development

 

 

 

 

 

Unaudited

Unaudited

Audited

 

6 months

6 months

Year

 

ended

ended

ended

 

30 Sept

30 Sept

31 March

 

2016

2015

2016

 

€'000

€'000

€'000

 

 

 

 

Revenue

714

2,205

5,422

Cost of sales

-

-

-

 

 

 

 

Gross profit/(loss)

714

2,205

5,422

 

 

 

 

Other operating costs

(6,308)

(5,420)

(10,063)

 

 

 

 

Loss from operations

(5,594)

(3,215)

(4,641)

 

 

 

 

Loss from Operations

(5,594)

(3,215)

(4,641)

Depreciation and amortisation

341

281

609

EBITDA

(5,253)

(2,934)

(4,032)

 

Manufacturing

 

 

 

 

Revenue

24,345

24,089

47,347

Cost of sales

(18,236)

(16,916)

(34,597)

 

 

 

 

Gross profit/(loss)

6,109

7,173

12,750

 

 

 

 

Other operating costs

(3,297)

(3,205)

(6,487)

Other gain

601

-

-

 

 

 

 

Profit/(loss) from operations

3,413

3,968

6,263

 

 

 

 

Profit/(loss) from operations

3,413

3,968

6,263

Depreciation and amortisation

1,057

1,022

2,016

EBITDA

4,470

4,989

8,279

 

Research and development

 

 

 

 

Revenue

-

-

-

Cost of sales

-

-

-

 

 

 

 

Gross profit/(loss)

-

-

-

 

 

 

 

Other operating costs

(571)

(764)

(1,910)

 

 

 

 

Loss from operations

(571)

(764)

(1,910)

 

 

 

 

Loss from Operations

(571)

(764)

(1,910)

Depreciation and amortisation

26

23

47

EBITDA

(545)

(741)

(1,863)

 

Total

 

 

 

 

Revenue

25,059

26,294

52,769

Cost of sales

(18,236)

(16,916)

(34,597)

 

 

 

 

Gross profit/(loss)

6,823

9,378

18,172

 

 

 

 

Other operating costs

(10,176)

(9,389)

(18,460)

Other gain

601

-

-

 

 

 

 

Loss from operations

(2,752)

(11)

(288)

 

 

 

 

Finance income

1

17

13

Finance expense

(104)

(98)

(191)

 

 

 

 

 

 

 

 

Loss before taxation

(2,855)

(92)

(466)

 

 

 

 

 

 

 

 

Loss from Operations

(2,752)

(11)

(288)

Depreciation and amortisation

1,423

1,325

2,672

EBITDA

(1,329)

1,314

2,384

 

Licensing, Management and Business Development

Revenue is attributable to the licensing of the Group's technology to third parties and other monies received in respect of its business development activities.

Other operating costs include all remaining costs unless they are directly attributable to Manufacturing or Research and Development. This includes marketing, business development and the majority of the Group's administration costs including the head office in London (previously Windsor) as well as the US office.

Headcount = 27 (2015: 22)

Manufacturing

Revenue includes the sale of Accoya® and other revenue, principally relating to the sale of acetic acid. All costs of sales are allocated against manufacturing activities unless they can be directly attributable to a licensee.

Other operating costs include depreciation of the Accoya plant all other costs associated with the operation of the manufacturing site, including directly attributable administration costs.

Headcount = 86 (2015: 84)

Research and Development

Costs are associated with various R&D activities associated with Accoya® and Tricoya® products and processes.

Headcount = 12 (2015: 13)

Assets and liabilities cannot be readily allocated to the three segments and therefore no additional segmental information has been disclosed.

 

Analysis of revenue by geographical destination:

 

 

Unaudited

Unaudited

Audited

 

6 months

6 months

Year

 

ended

ended

ended

 

30 Sept

30 Sept

31 March

 

2016

2015

2016

 

€'000

€'000

€'000

 

 

 

 

 UK and Ireland

10,577

9,571

21,426

 Rest of Europe

5,924

7,868

14,085

 Benelux

3,762

3,904

7,764

 Americas

2,849

2,449

4,846

 Asia-Pacific

1,814

2,345

4,382

 Rest of World

133

156

266

 

 

 

 

 

25,059

26,294

52,769

 

The segmental assets in the current and previous periods were predominantly held in Europe. Additions to property, plant, equipment and intangible assets in the current and previous periods were predominantly incurred in Europe. Sales to UK and Ireland included the sales to Medite. 

 

 

3. Other operating costs

 

Other operating costs consist of the operating costs, other than the cost of sales, associated with the operation of the plant in Arnhem and the offices in Dallas and London (previously Windsor).

 

 

 

 

Unaudited

Unaudited

Audited

 

 

 

6 months

6 months

Year

 

 

 

ended

ended

ended

 

 

 

30 Sept

30 Sept

31 March

 

 

 

2016

2015

2016

 

 

 

€'000

€'000

€'000

 

 

 

 

 

 

Sales and marketing

 

2,006

1,805

3,743

Research and development

571

764

1,863

Depreciation and amortisation

1,423

1,326

2,672

Other operating costs

 

2,259

2,097

3,554

Administration costs

 

3,917

3,397

6,628

 

 

 

 

 

 

 

 

 

10,176

9,389

18,460

 

 

 

 

 

 

Administrative costs include costs associated with Business Development and Legal departments, Intellectual Property as well as Human Resources, IT, Finance, Management and General Office and include the costs of the Group's head office costs in London (previously Windsor) and the US office in Dallas.

 

The total cost of €10.2m in the current period includes €1.4m in respect of Tricoya Technologies Limited ('TTL') compared to €0.9m in the previous period.

 

The Group headcount increased from 119 during period to 30 September 2015 to 121 during period to 31 March 2016 and then to 125 to period to 30 September 2016.

 

During the period €0.2m of costs were capitalised and are included within intangible fixed assets (2015: €1.2m). In addition €0.3m of development costs have been capitalised and are included within tangible fixed assets (2015: €0.5m) in relation to the expansion of the manufacturing facility in Arnhem. The previous period figure includes €1m in respect of the Tricoya® Front End Engineering and Design Package.

 

4. Other gains

 

 

 

Unaudited

Unaudited

Audited

 

 

 

6 months

6 months

Year

 

 

 

ended

ended

ended

 

 

 

30 Sept

30 Sept

31 March

 

 

 

2016

2015

2016

 

 

 

€'000

€'000

€'000

Gain from disposal of land

 

 

635

-

-

Net gain/(loss) from disposal of equipment

 

 

(34)

-

-

 

 

 

601

-

-

 

 

 

 

 

 

Agreements were reached in August 2016 for the sale and leaseback for the land in Arnhem resulting in proceeds of €4.2m received in the period. A resulting gain of €635,000 was recognised as a result of the book value of the land being lower than the sale price. Under the arrangements, the landlord has agreed to construct a new warehouse and office building which will be connected to Accsys's existing manufacturing site. This building will be built by the landlord and leased to Accsys over a 20 year period with further option to renew. The landlord is the same landlord that Accsys sold land and buildings to in 2011 and 2012 associated with the existing manufacturing plant.

   

 

5. Loss per share

 

 

Unaudited

Unaudited

Audited

 

6 months

6 months

Year

 

ended

ended

ended

Basic and diluted loss per share

30 Sept2016

30 Sept2015

31 March2016

 

Total

Total

Total

Weighted average number ofOrdinary shares in issue ('000)

 

 

 

90,248

89,287

89,568

 

 

 

Loss for the period (€'000)

(3,186)

(332)

(858)

 

 

 

 

Basic and diluted loss per share

€(0.04)

€(0.00)

€(0.01)

 

 

 

 

Basic and diluted losses per share are based upon the same figures. Share options are considered anti-dilutive as these would increase the loss per share.

 

6. Tricoya Technologies Limited

 

Tricoya Technologies Limited ('TTL'), was incorporated in order to develop and exploit Accsys' Tricoya technology for use within the worldwide panel products market estimated to be worth more than €60 billion annually.

 

In February 2016 BP's participation in the proposed consortium (the 'Consortium') to fund, build and operate the world's first Tricoya® wood elements acetylation plant was announced. Accsys and BP Ventures ('BPV') agreed initial funding in respect of the Consortium, with BPV acquiring an initial 3% equity interest in Tricoya Technologies Limited ('TTL'), implying a valuation of TTL at €35 million today. The plant is expected to be located at the Saltend Chemicals Park in Hull, UK, adjacent to BP's existing acetyls facility.

 

Since then, significant progress has been made with our Consortium partners, BP and Medite, in respect of detailed planning and the agreements associated with the Consortium and the proposed wood chip acetylation plant. The Hull plant will have an initial capacity of 30,000 tonnes per annum (tpa) (sufficient to manufacture 40,000m³ of panels) with scope for expansion. A minimum of 40% of the plant's output is expected to be sold to Medite under committed take-or-pay agreements, which corresponds to break-even cash flow level. The plant is expected to cost approximately €62m, with a further €14m required for continued market seeding, operations, marketing, IP development and engineering functions.

 

Final agreements relating to the Consortium, the site, the supply of chemicals from BP and the off-take agreement with Medite are expected to be completed by the end of the year. BP and Medite are also expected to invest a total of €30m with the remainder funded by third parties, including bank debt. In this respect, the Consortium has also made good progress on securing finance with term sheets received from a number of providers of project finance debt and heads of terms agreed with further third party providers of finance which is expected to result in sufficient funding to allow the Consortium to be completed.

 

Subsequent to the period end, the Consortium parties agreed further interim funding to enable the next stages of the project to progress, including the land clearance of the site in Hull and initial steps associated with the detailed engineering.

 

There was increased activity in the current period in relation to preparing to commence detailed work following completion of the Consortium agreements. The increased cost consists of higher staff costs, research and development and Intellectual Property.

 

During the period ended 30 September 2016, TTL has been fully consolidated and the results are included as part of the overall group results and included within the Business Development segment as set out in Note 2.

 

Subsequent to the period end, the Consortium parties agreed further interim funding to enable the next stages of the project to progress, including the land clearance of the site in Hull and initial steps associated with the detailed engineering.

 

The TTL results for the period from 1 April 2016 to 30 September 2016, together with the balance sheet as at 30 September 2016 are set out below: 

 

 

 

Income statement for TTL:

 

Consolidated

Consolidated

Consolidated

 

Unaudited

Unaudited

Audited

 

6 months

6 months

Year

 

ended

ended

ended

 

30 Sept

30 Sept

31 March

 

2016

2015

2016

 

€'000

€'000

€'000

 

 

 

 

Licence revenue

-

75

75

Other income

23

30

243

Total revenue

23

105

318

 

 

 

 

Costs:

 

 

 

Staff costs

814

612

864

Research & development (excluding staff costs)

38

60

142

Intellectual Property

338

151

303

Sales & marketing

26

18

214

Amortisation

84

66

143

Total operating costs

1,300

907

1,666

 

 

 

 

Finance income

-

-

-

 

 

 

 

EBIT

1,277

802

1,348

 

 

 

 

Group share of EBIT

1,235

802

1,338

 

 

 

 

 

 

 

Tricoya Technologies Limited statement of financial position at 30 September 2016:

 

 

Unaudited

Unaudited

Audited

 

6 months

6 months

Year

 

ended

ended

ended

 

30 Sept

30 Sept

31 March

 

2016

2015

2016

 

€'000

€'000

€'000

 

 

 

 

Non-current assets

 

 

 

Intangible assets

3,192

2,899

3,065

 

 

 

 

Current assets

 

 

 

Receivables due within one year

160

160

230

Cash and cash equivalents

298

117

1,519

 

 

 

 

Total current assets

458

277

1,749

 

 

 

 

Current liabilities

 

 

 

Trade and other payables

(2,404)

(2,099)

(2,220)

 

 

 

 

Net current assets

(1,946)

(1,822)

(471)

 

 

 

 

Net assets

1,246

1,078

2,594

 

 

 

 

97% attributable to Accsys Technologies 2016 (2015: 100%)

1,209

1,078

2,517

 

 

 

 

Less elimination of mark-up on recharged costs

-

(14)

-

 

 

 

 

 

 

 

 

Equity and reserves

 

 

 

Share capital

8,206

5,900

8,206

Accumulated loss

(7,560)

(5,422)

(6,212)

Other reserves

600

600

600

Total equity

1,246

1,078

2,594

 

 

 

 

 

Intangible assets represents internal development costs capitalised relating to the development of the Tricoya product and production process, including Front End Engineering and Design which has been undertaken in the period in respect of the first Tricoya production plant envisaged to be funded, constructed and operated by the proposed new Consortium.

 

 

 

 

7. Intangible assets

 

 

 

Internal

Intellectual

 

 

 

Development

property

 

 

 

costs

rights

Goodwill

Total

 

€'000

€'000

€'000

€'000

 

 

 

 

 

Cost

 

 

 

 

At 31 March 2015

4,037

73,292

4,231

81,560

 

 

 

 

 

Additions

1,206

-

-

1,206

 

 

 

 

 

At 30 September 2015

5,243

73,292

4,231

82,766

 

 

 

 

 

Additions

285

-

-

285

 

 

 

 

 

At 31 March 2016

5,528

73,292

4,231

83,051

 

 

 

 

 

Additions

241

-

-

241

 

 

 

 

 

At 30 September 2016

5,769

73,292

4,231

83,292

 

 

 

 

 

Accumulated amortisation

 

 

 

 

At 31 March 2015

358

71,188

-

71,546

 

 

 

 

 

Amortisation

117

138

-

255

 

 

 

 

 

At 30 September 2015

475

71,326

-

71,801

 

 

 

 

 

Amortisation

132

138

 

270

 

 

 

 

 

At 31 March 2016

607

71,464

-

72,071

 

 

 

 

 

Amortisation

138

138

 

276

 

 

 

 

 

At 30 September 2016

745

71,602

-

72,347

 

 

 

 

 

 

 

 

 

 

Net book value

 

 

 

 

At 30 September 2016

5,024

1,690

4,231

10,945

 

 

 

 

 

 

 

 

 

 

At 31 March 2016

4,921

1,828

4,231

10,980

 

 

 

 

 

 

 

 

 

 

At 30 September 2015

4,768

1,966

4,231

10,965

 

 

 

 

 

 

 

 

 

 

At 31 March 2015

3,679

2,104

4,231

10,014

 

 

 

 

 

 

 

 

 

 

 

 

8. Property, plant and equipment

 

Land and buildings

 

Plant and machinery

 

Office equipment

 

Total

 

€'000

 

€'000

 

€'000

 

€'000

Cost or valuation

 

 

 

 

 

 

 

At 31 March 2015

5,251

 

28,365

 

822

 

34,438

 

 

 

 

 

 

 

 

Additions

-

 

682

 

46

 

728

Disposals

-

 

-

 

(12)

 

(12)

Foreign currency translation (loss)

-

 

-

 

(7)

 

(7)

 

 

 

 

 

 

 

 

At 30 September 2015

5,251

 

29,047

 

849

 

35,147

 

 

 

 

 

 

 

 

Additions

-

 

1,792

 

389

 

2,181

Disposals

-

 

(114)

 

1

 

(113)

Foreign currency translation gain

-

 

-

 

(1)

 

(1)

 

 

 

 

 

 

 

 

At 31 March 2016

5,251

 

30,725

 

1,238

 

37,214

 

 

 

 

 

 

 

 

Additions

-

 

1,343

 

53

 

1,396

Disposals

(3,606)

 

(64)

 

-

 

(3,670)

Foreign currency translation (loss)

-

 

-

 

2

 

2

 

 

 

 

 

 

 

 

At 30 September 2016

1,645

 

32,004

 

1,293

 

34,942

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

 

 

 

 

 

At 31 March 2015

424

 

13,732

 

734

 

14,890

 

 

 

 

 

 

 

 

Charge for the period

59

 

971

 

45

 

1,075

Disposals

-

 

-

 

(12)

 

(12)

Foreign currency translation (loss)

-

 

-

 

(7)

 

(7)

 

 

 

 

 

 

 

 

At 30 September 2015

483

 

14,703

 

760

 

15,946

 

 

 

 

 

 

 

 

Charge for the period

58

 

941

 

74

 

1,073

Disposals

-

 

(76)

 

-

 

(76)

Foreign currency translation gain

-

 

-

 

(1)

 

(1)

 

 

 

 

 

 

 

 

At 31 March 2016

541

 

15,568

 

833

 

16,942

 

 

 

 

 

 

 

 

Charge for the period

59

 

947

 

84

 

1,090

Disposals

-

 

(6)

 

-

 

(6)

Foreign currency translation (loss)

-

 

-

 

2

 

2

 

 

 

 

 

 

 

 

At 30 September 2016

600

 

16,509

 

919

 

18,028

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net book value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 31 March 2015

4,827

 

14,633

 

88

 

19,548

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 September 2015

4,768

 

14,344

 

89

 

19,201

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 31 March 2016

4,710

 

15,157

 

405

 

20,272

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 30 September 2016

1,045

 

15,495

 

374

 

16,914

 

 

 

 

 

 

 

 

 

9. Share capital

 

In the period ended 30 September 2015:

 

Own shares represents 786,893 ordinary shares of €0.05 each in the capital of the Company ("Ordinary Shares") issued to an Employee Benefit Trust ('EBT') at nominal value on 30 June 2015.

 

On 6 July 2015, a total of 20,000 Ordinary Shares were issued to employees under the Company's share option scheme.

 

In addition, of the 783,597 Ordinary Shares which had been issued to the EBT at nominal value on 18 August 2014, 746,241 Ordinary Shares vested on 1 July 2015. Of these beneficiaries elected to sell 390,683 Ordinary Shares in the market.

 

On 8 August 2015, a total of 27,825 Ordinary Shares were issued and released to employees together with the 22,825 Ordinary Shares issued to an employee trust on 8 August 2014 under the terms of the Employee Share Participation Plan (the "Trust").

 

On 13 August 2015, a total of 63,909 Ordinary Shares were issued to a trust under the terms of the Trust.

 

In the period ended 31 March 2016:

 

On 10 December 2015, a total of 16,123 Ordinary Shares were issued to a Trust under the terms of the Employee Share Participation Plan.

 

In the period ended 31 September 2016:

 

Own shares represents 673,355 Ordinary Shares issued to the EBT at nominal value on 4 July 2016.

 

In addition, of the Ordinary Shares which had been issued to the EBT previous year, 938,449 Ordinary Shares vested on 15 July 2016. Of these beneficiaries elected to sell 498,318 Ordinary Shares in the market.

 

On 15 August 2016, a total of 63,909 Ordinary Shares were issued and released to various employees under the terms of the Employee Share Participation Plan.

 

 

10. Other Reserves

 

Capital redemp-tion reserve

Warrant reserve

Merger reserve

Other reserve

Total Other reserves

 

€000

€000

€000

€000

€000

Balance at 30 September 2015

148

-

106,707

-

106,855

 

 

 

 

 

 

Issue of subsidiary shares to non-controlling interests

(299)

-

-

885

586

 

 

 

 

 

 

Balance at 31 March 2016

(151)

-

106,707

885

107,441

 

 

 

 

 

 

Adjustment to liability relating to non-controlling interests

(20)

-

-

-

(20)

 

 

 

 

 

 

Balance at 30 September 2016

(171)

-

106,707

885

107,421

 

 

 

 

 

 

 

 

The opening balance from September 2015 of the capital redemption reserve represents the amounts transferred from share capital on redemption of deferred shares in a previous period. The movement for the year ended 31 March 2016 and in the

 

 

current period reflects obligations arising from the investment by BP Ventures into Tricoya Technologies Limited and that BP Venture's on-going participation is conditional upon the finalisation of the full proposed Consortium.

 

The merger reserve arose prior to transition to IFRS when merger accounting was adopted.

 

The other reserve represents the amounts received for subsidiary share capital from non-controlling interests (note 11).

 

 

 

11. Transactions with non-controlling interests

 

On 3 February 2016, TTL issued 500,000 Series A Preference shares for the consideration of €1m for 3% equity share capital of TTL. The carrying amount of the non-controlling interests in TTL on the date of acquisition was €71,000. The Group recognised an increase in other reserves in the prior period, as summarised below.

 

 

Transactions with non-controlling interests

 

 

 

Unaudited

Unaudited

Audited

 

 

 

 

6 months

6 months

Year

 

 

 

 

ended

ended

ended

 

 

 

 

30 Sept

30 Sept

31 March

 

 

 

 

2016

2015

2016

 

 

 

 

€'000

€'000

€'000

Carrying amount of non-controlling interests issued

 

 

 

885

-

(71)

Consideration paid by non-controlling interests

 

 

 

-

-

1,000

Share issue costs relating to non-controlling interests

 

 

 

-

-

(44)

Excess of consideration paid recognised in Group's equity

 

 

 

885

-

885

 

 

 

 

 

 

 

12. Events occurring after the reporting period

 

On 24 October 2016, TTL issued further shares for the consideration of €1m. €0.4m was contributed by Accsys with €0.6m contributed by BP Ventures, bringing their total investment to €1.6m.

 

Accsys Technologies PLC

 

Independent review report to Accsys Technologies PLC

 

Our conclusion

 

We have reviewed Accsys Technologies PLC's consolidated interim financial statements (the "interim financial statements") in the interim results for the six months ended 30 September 2016 of Accsys Technologies Plc for the 6 month period ended 30 September 2016. Based on our review, nothing has come to our attention that causes us to believe that the interim financial statements are not prepared, in all material respects, in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union and the AIM Rules for Companies.

 

What we have reviewed

 

The interim financial statements comprise:

 

· the consolidated interim statement of financial position as at 30 September 2016;

· the consolidated interim statement of comprehensive income for the period then ended;

· the consolidated interim statement of cash flows for the period then ended;

· the consolidated interim statement of changes in equity for the period then ended; and

· the explanatory notes to the interim financial statements.

The interim financial statements included in the interim results for the six months ended 30 September 2016 have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union and the AIM Rules for Companies.

 

As disclosed in note 1 to the interim financial statements, the financial reporting framework that has been applied in the preparation of the full annual financial statements of the Group is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union.

 

Our responsibilities and those of the directors

 

The interim results for the six months ended 30 September 2016, including the interim financial statements, is the responsibility of, and has been approved by, the directors of the Company. The directors are responsible for preparing the interim results for the six months ended 30 September 2016 in accordance with the AIM Rules for Companies which require that the financial information must be presented and prepared in a form consistent with that which will be adopted in the Company's annual financial statements.

 

Our responsibility is to express a conclusion on the interim financial statements in the interim results for the six months ended 30 September 2016 based on our review. This report, including the conclusion, has been prepared for and only for the Company for the purpose of complying with the AIM Rules for Companies and for no other purpose. We do not, in giving this conclusion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

 

What a review of interim financial statements involves

 

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.

 

A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

 

We have read the other information contained in the interim results for the six months ended 30 September 2016 and considered whether it contains any apparent misstatements or material inconsistencies with the information in the interim financial statements.

 

 

PricewaterhouseCoopers LLPChartered Accountants

London

 

21 November 2016

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LFFEILSLLFIR
Date   Source Headline
28th Mar 202412:00 pmRNSDirector Interests
1st Mar 20247:00 amRNSBlock listing Six Monthly return
27th Feb 20247:00 amRNSBlock listing application to AIM
12th Dec 20237:00 amRNSDirectorate Change
27th Nov 20239:57 amRNSNotifiable Interest - De Engh B.V.
27th Nov 20239:33 amRNSNotifiable Interest – Teslin
24th Nov 202312:21 pmRNSNotifiable Interest – De Engh B.V.
21st Nov 20233:37 pmRNSResults of Capital Raise
21st Nov 20237:04 amRNSHalf-year Report
21st Nov 20237:00 amRNSIssue of Equity
20th Sep 20235:12 pmRNSResults of Annual General Meeting 2023
15th Sep 20233:54 pmRNSNotifiable Interest - De Engh
12th Sep 20237:00 amRNSDirectorate Change
1st Sep 20237:00 amRNSBlock Listing Six Monthly Return
1st Sep 20237:00 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTrading Update
17th Aug 20235:01 pmRNSNotice of Annual General Meeting 2023
28th Jul 20237:00 amRNSDirector Interests and LTIP Awards
26th Jul 20237:00 amRNSDirectorate Appointment
21st Jul 20233:46 pmRNSAnnual Report and Financial Statements 2023
27th Jun 20237:00 amRNSPreliminary results for the year end 31 March 2023
19th Jun 202312:48 pmRNSChange of Registered Office
6th Jun 20237:00 amRNSDirectorate Update
12th May 202311:21 amRNSBlock Listing Application to AIM
3rd May 20237:00 amRNSTrading Update
4th Apr 20237:00 amRNSCEO Appointment
24th Mar 20237:00 amRNSDirectorate Appointments
2nd Mar 20236:00 pmRNSBlock Listing Six Monthly Return
2nd Mar 20236:00 pmRNSTotal Voting Rights
26th Jan 20237:00 amRNSAccsys Trading Update
15th Dec 20223:55 pmRNSDirector/PDMR Shareholding
12th Dec 20227:00 amRNSDirectorate Change
6th Dec 20223:43 pmRNSNotifiable Interest - De Engh
6th Dec 20223:36 pmRNSNotifiable Interest - Teslin Participaties
22nd Nov 20227:00 amRNSInterim Results for six months ended 30 Sept 2022
17th Nov 20222:58 pmRNSIssue of Equity
10th Nov 20224:37 pmRNSHolding(s) in Company
8th Nov 20225:09 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSUpdate on Tricoya – Consortium restructure
1st Nov 20224:12 pmRNSNotice of HY Results and Total Voting Rights
23rd Sep 20224:20 pmRNSResult of AGM
12th Sep 20227:00 amRNSAccsys Trading Update
23rd Aug 20224:49 pmRNSNotice of AGM
23rd Aug 20222:35 pmRNSBlock Listing Application to AIM
3rd Aug 20227:00 amRNSDirectorate Change
27th Jul 20225:56 pmRNSAnnual Report
12th Jul 202210:40 amRNSDirector Interests and LTIP Awards
12th Jul 202210:16 amRNSGrant of Awards under Accsys Deferred Bonus Plan
30th Jun 20227:00 amRNSPreliminary results for the year end 31 March 2022
10th Jun 20227:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.